These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
410 related articles for article (PubMed ID: 28971503)
41. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation. Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639 [TBL] [Abstract][Full Text] [Related]
42. Autologous stem cell transplantation and stem cell mobilization kinetics in elderly patients with B cell non-Hodgkin lymphoma. Dogu MH; Çagirgan S; Ocakci S; Kaya AH; Ilkkilic K; Sanli NM; Kahraman S; Eren R; Tekgunduz E; Hacioglu S; Kaynar L; Erkurt MA; Altuntas F Transfus Apher Sci; 2017 Dec; 56(6):814-818. PubMed ID: 29153347 [TBL] [Abstract][Full Text] [Related]
43. Impact of Radiation Therapy After High Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Lymphomas: A Single Center Experience. Osmani AH; Khafaga Y; Rauf MS; Maghfoor I; Akhtar S Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):e149-e160. PubMed ID: 34627735 [TBL] [Abstract][Full Text] [Related]
44. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. Sweetenham JW; Carella AM; Taghipour G; Cunningham D; Marcus R; Della Volpe A; Linch DC; Schmitz N; Goldstone AH J Clin Oncol; 1999 Oct; 17(10):3101-9. PubMed ID: 10506605 [TBL] [Abstract][Full Text] [Related]
45. Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL. Moore S; Kayani I; Peggs K; Qian W; Lowry L; Thomson K; Linch DC; Ardeshna K Br J Haematol; 2012 Jun; 157(5):543-52. PubMed ID: 22429186 [TBL] [Abstract][Full Text] [Related]
46. Influence of ex vivo purging with CliniMACS CD34(+) selection on outcome after autologous stem cell transplantation in non-Hodgkin lymphoma. Yahng SA; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Min WS; Park CW; Kim Y; Cho SG Br J Haematol; 2014 Feb; 164(4):555-64. PubMed ID: 24266323 [TBL] [Abstract][Full Text] [Related]
47. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center. Kopińska A; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kata D; Włodarczyk M; Helbig G Pathol Oncol Res; 2021; 27():1609867. PubMed ID: 34385892 [No Abstract] [Full Text] [Related]
48. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation. Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G; Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180 [TBL] [Abstract][Full Text] [Related]
49. High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma. Akhtar S; El Weshi A; Rahal M; Abdelsalam M; Al Husseini H; Maghfoor I Bone Marrow Transplant; 2010 Mar; 45(3):476-82. PubMed ID: 19734949 [TBL] [Abstract][Full Text] [Related]
50. Treatment of multiple myeloma. San Miguel JF; Bladé Creixenti J; García-Sanz R Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392 [TBL] [Abstract][Full Text] [Related]
51. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer]. Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945 [TBL] [Abstract][Full Text] [Related]
52. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Milgrom SA; Jauhari S; Plastaras JP; Nieto Y; Dabaja BS; Pinnix CC; Smith GL; Allen PK; Lukens JN; Maity A; Oki Y; Fanale MA; Nasta SD Cancer; 2017 Apr; 123(8):1363-1371. PubMed ID: 27984652 [TBL] [Abstract][Full Text] [Related]
54. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO). García-Noblejas A; Cannata-Ortiz J; Conde E; González Barca E; Gutiérrez N; Rojas R; Vidal MJ; Ramírez MJ; Jiménez-Ubieto A; García-Ruiz JC; Sancho JM; López A; Ríos Rull P; Novelli S; Albo C; Debén G; López-Guillermo A; Nicolás C; González de Villambrosia S; Mercadal S; Martín García-Sancho A; Arranz R Ann Hematol; 2017 Aug; 96(8):1323-1330. PubMed ID: 28536895 [TBL] [Abstract][Full Text] [Related]
55. [Novel treatment options in relapsed and refracter Hodgkin lymphomas]. Illés Á; Jóna Á; Simon Z; Udvardy M; Miltényi Z Orv Hetil; 2015 Nov; 156(45):1824-33. PubMed ID: 26522856 [TBL] [Abstract][Full Text] [Related]
56. The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant. Furlan C; Matrone F; Rupolo M; Ciancia R; Zanet E; Montante B; Palazzari E; Navarria F; Trovo M; Bulian P; Spina M; Coassin E; Mascarin M; De Paoli A; Franchin G; Michieli M Cancer Radiother; 2019 Sep; 23(5):378-384. PubMed ID: 31178272 [TBL] [Abstract][Full Text] [Related]
57. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Blaise D; Peggs KS; Afanasyev B; Diez-Martin JL; Corradini P; Michonneau D; Robinson S; Gutiérrez García G; Bonifazi F; Yakoub-Agha I; Gülbas Z; Bloor A; Delage J; Esquirol A; Malladi R; Scheid C; El-Cheikh J; Ghesquières H; Montoto S; Dreger P; Sureda A Cancer; 2019 Jan; 125(1):90-98. PubMed ID: 30351488 [TBL] [Abstract][Full Text] [Related]